Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Relapsed or resistant follicular non-Hodgkin's lymphoma (NHL)~  * No evidence of transformation to high grade or diffuse large B-cell NHL~* CD20 positive with no evidence of transformation~* Achievement of complete remission (CR) or very good partial remission (VGPR) following reinduction chemotherapy with any standard regimen~  * Includes patients who fail to respond to first-line chemotherapy but who achieve CR or VGPR after proceeding directly to second-line chemotherapy~* Platelet count greater than 100,000/mm\^3 after induction chemotherapy and before randomization~* No CNS involvement~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Bilirubin normal~* ALT no greater than 2 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2 times ULN~* Hepatitis B negative~* Hepatitis C negative~Renal:~* Creatinine no greater than 2 times ULN~* BUN no greater than 2 times ULN~Cardiovascular:~* No inadequate cardiac function~Pulmonary:~* No inadequate pulmonary function~Other:~* Not pregnant or nursing~* HIV negative~* No other uncontrolled serious medical conditions~* No other malignancy within the past 5 years except nonmelanoma skin tumors or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* More than 12 months since prior CD20 therapy, including rituximab~* No prior peripheral blood stem cell transplantation~Chemotherapy:~* See Disease Characteristics~* No more than 3 prior chemotherapy regimens for NHL~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to greater than 30% of bone marrow~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).